CID16020046

  • CAS
  • Size
  • Purity
  • Price
  • Availability
  • Quantity
  • Order

If you have any other questions or need other size, please get a quote.

Catalog Number
ACM834903434
Product Name
CID16020046
CAS
834903-43-4
Category
Agonists
Description
CID16020046 is a selective GPR55 inverse agonist. CID16020046 is a G protein-coupled receptor that is weakly activated by some cannabinoids at nM concentrations. CID16020046 has been shown to block GPR55-mediated endothelial wound healing and reverse LPI-inhibited platelet aggregation.
Synonyms
CID16020046; CID-16020046; CID 16020046
IUPAC Name
4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-1,4-dihydropyrrolo[3,4-d]pyrazol-5-yl]benzoic acid
Molecular Weight
425.44
Molecular Formula
C25H19N3O4
Canonical SMILES
O=C(O)C1=CC=C(N(C2=O)C(C3=CC=CC(O)=C3)C4=C2NN=C4C5=CC=C(C)C=C5)C=C1
InChI
InChI=1S/C25H19N3O4/c1-14-5-7-15(8-6-14)21-20-22(27-26-21)24(30)28(18-11-9-16(10-12-18)25(31)32)23(20)17-3-2-4-19(29)13-17/h2-13,23,29H,1H3,(H,26,27)(H,31,32)
InChI Key
VGUQVYZXABOXCX-UHFFFAOYSA-N
Solubility
Soluble in DMSO
Appearance
Solid powder
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Biological Target
CID 16020046 is a potent and selective GPR55 antagonist and inhibits GPR55 constitutive activity with an IC50 of 0.15 μM.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 70.58; H, 4.50; N, 9.88; O, 15.04
Exact Mass
425.1376
HS Tariff Code
2934.99.9001
In Vitro Activity
This study showed that AGEs dose dependently induced GPR55 expression in ATDC5 chondrocytes. The blockage of GPR55 by its newly discovered antagonist-CID16020046 mitigated AGEs- induced increase in cellular ROS and decrease in antioxidant NRF2.
Reference: Chem Biol Interact. 2020 Jul 1;325:109088. https://pubmed.ncbi.nlm.nih.gov/32360554/
In Vivo Activity
Further analysis of the component pain-related behaviours revealed that CID16020046 significantly reduced the duration of biting/licking/flinching behaviour (Pain 2) during the second phase of the formalin trial (Fig. 2C). Duration of paw elevation (Pain 1) during the second phase was also lower in CID16020046-treated rats but this effect did not reach statistical significance (Fig. 2B).
Reference: Neuroscience. 2020 Sep 1;443:19-29. https://pubmed.ncbi.nlm.nih.gov/32673629/
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).
Please kindly note that our products are for research use only.

Discover More

Contact Us

For product inquiries, please use our online system or send an email to .

Download
Verification code
* I hereby give my consent that I may receive marketing e-mails with information on existing and new services from this company. I know that I can opt-out from receiving such e-mails at any time or by using the link which will be provided in each marketing e-mail.
qrcode